Quarterly ResultAug 11, 2026, 04:14 PM
BridgeBio Oncology Q2 Net Loss $56.5M; Cash Runway into 2028
AI Summary
BridgeBio Oncology Therapeutics reported a net loss of $56.5 million for the second quarter of 2026, an increase from $28.4 million in Q2 2025, driven by higher R&D and G&A expenses. The company announced significant progress in its clinical programs, including advancing monotherapy and combination cohorts for its RAS-pathway inhibitors and initiating new combination dosing. As of June 30, 2026, BBOT held $344.1 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2028.
Key Highlights
- Cash, cash equivalents, and marketable securities totaled $344.1 million as of June 30, 2026.
- Cash runway is expected to fund operations into 2028.
- R&D expenses were $49.2 million for Q2 2026, up from $27.4 million in Q2 2025.
- G&A expenses were $11.0 million for Q2 2026, up from $2.7 million in Q2 2025.
- Net loss was $56.5 million for Q2 2026, compared to $28.4 million in Q2 2025.
- Continued to advance monotherapy and combination cohorts for all clinical programs.
- Initiated dosing of BBO-11818 in combination with cetuximab and BBO-10203.
- Presented preclinical data at AACR for BBO-11818 and BBO-10203.
Price Impact
More from BBOT